flâneur

Sensitizing to Venetoclax treatment

mappingignorance.org · 2,007 words · saved by 1 readers

Acute Myeloid Leukemia (AML) is a hematopoietic neoplasm characterized by the proliferation and accumulation of aberrant immature myeloid progenitor cells. AML is associated with poor clinical outcome and high mortality, with an overall five-year survival rate of less than 15-30%. For AML patients, standard therapies often fail to achieve the complete remission, disease relapse is often fatal and bone marrow transplantation are only applicable to a few selected AML patients, highlighting the need for novel targeted treatments. A number of such emerging treatments have targeted essential “hallmarks” of cancer, including the regulation of cancer cell survival by members of the BCL-2 protein family. Among these members, B-cell lymphoma 2 (BCL-2) has been found to be upregulated in AML cells 1 and, specifically, in leukemic stem cells (LSC) 2. Besides, BCL-2 overexpression is a poor-prognosis factor in AML and is associated with poor response to standard cytotoxic therapy 3. Mechanisticall

Easy text A+ A++ 🌙 9 min Targeting mitochondrial structure sensitizes acute myeloid leukemia to Venetoclax treatment Author: Marta Irigoyen is a postdoctoral researcher at CIC bioGUNE Acute Myeloid Leukemia (AML) is a hematopoietic neoplasm characterized by the proliferation and accumulation of aberrant immature myeloid progenitor cells. AML is associated with poor clinical outcome and high mortality, with an overall five-year survival rate of less than 15-30%. For AML patients, standard therapies often fail to achieve the complete remission, disease relapse is often fatal and bone marrow tra

related reading